Article

2011 ACC VIDEO: Cost Analysis Substituting Dabigatran for Warfarin

Dr. Julie Atay discusses the two main objectives of her poster which evaluated the cost analysis of substituting Dabigatran for Warfarin.

Dr. Julie Atay discusses her poster, "Cost Analysis of Substituting Dabigatran for Warfarin in an Anticoagulant Management Program," at ACC's 60th Annual Scientific Sessions. Dr. Atay provides a quick explanation about the two objectives her colleagues and she were evaluating: 1) The percentage of patients already on Warfarin who qualified to be on Dabigatran; and 2) The direct costs associated with switching patients from Warfarin to Dabigatran.

Related Videos
Experts' Perspectives: Top Stories in Cardiology for 2024
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
© 2024 MJH Life Sciences

All rights reserved.